Hormone Receptor Articles & Analysis
18 news found
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as a ...
Almost 70% of breast cancers are hormone-receptor positive. The majority of these patients are receiving well-established adjuvant endocrine therapy (with the objective of reducing hormonal levels) for at least five years to reduce the recurrence of breast cancer and improving associated mortality. ...
ByBayer AG
A Phase I clinical study will be conducted in Chinese patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced/metastatic breast cancer, including patients who are resistant to approved CDK4/6 inhibitors, to evaluate the safety, tolerability and pharmacokinetic profile of RGT-419B capsule. ...
It is expected to combat the resistance to currently approved CDK4/6 inhibitors that are given in combination with endocrine-based therapy for treatment of pre/perimenopausal or postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer. The Phase I ...
It is expected to improve the safety of and combat the resistance to currently approved CDK4/6 inhibitors that are given in combination with endocrine-based therapy for treatment of pre/perimenopausal or postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic ...
” Ocugen’s modifier gene therapy platform aims to target nuclear hormone receptors (NHRs) that regulate multiple functions within the retina, giving it the potential to address many different gene mutations – and, in turn, multiple retinal diseases – with a single product. ...
Approximately one-third of patients diagnosed with hormone receptor (HR)-positive, HER2- negative early breast cancer have a tumor that has spread to their lymph nodes. ...
Approximately one-third of patients diagnosed with hormone receptor (HR)-positive, HER2- negative early breast cancer have a tumor that has spread to their lymph nodes. ...
One of the largest clinical trials in node-positive hormone receptor (HR)-positive, HER2-negative early breast cancer, RxPONDER enrolled more than 5,000 women with up to three positive nodes and successfully defined the benefit of chemotherapy in patients with Oncotype DX Breast Recurrence Score results of 0 to 25. ...
” The breast cancer investigations conducted so far at the University of Leeds using the 4D Q-plasia OncoReader Breast platform have focused on identifying the presence of breast cancer and determining its subtype, grade, HER2 and hormone receptor status from H&E stained whole slide biopsy images only. ...
“These results are practice changing and demonstrate that the great majority of postmenopausal women can be spared unnecessary chemotherapy and receive only hormone therapy. This should bring more clarity to physicians and some relief for patients.” Approximately 25% of patients diagnosed with hormone receptor (HR)-positive, ...
The findings highlight the value the Oncotype DX test can provide by personalising and improving neoadjuvant treatment decisions (i.e., prior to surgery) in women with hormone receptor positive, HER2-negative breast cancer. “As health systems across the world respond to the Covid-19 pandemic, decisions are being made that are resulting in the postponement ...
Clinical Outcomes in Patients with High Recurrence Score Results Presented in Oral Session at ESMO 2019 Congress With Fourth Peer-Reviewed Publication, TAILORx Continues to Elevate Oncotype DX Test to a New Global Standard Genomic Health on Monday announced results from a new analysis of the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, which reinforce the unique ...
Other key factors (e.g. histologic grade, continuous number of mitosis, HER2 and hormone receptor status, and Ki-67 poliferation index) might also be identified with the aid of this technology. ...
Novartis was the first company to present positive data for progression-free survival, the primary endpoint of the study for patients with hormone receptor-positive HER2-negative advanced breast cancer whose tumors have harbored a PI3-kinase ...
“It has been known for some time that breast cancers with differing receptor expression and gene amplification profiles have different risk factors for disease progression, as well as different preferential organ sites of metastases and therapeutic response. ...
Among women with a family history of breast cancer, those who worked with organic solvents prior to their first full-term birth had an increased risk for hormone receptor-positive breast cancer, according to data published in Cancer Research, a journal of the American Association for Cancer Research. ...
Among women with a family history of breast cancer, those who worked with organic solvents prior to their first full-term birth had an increased risk for hormone receptor-positive breast cancer, according to data published in Cancer Research, a journal of the American Association for Cancer Research. ...